AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
183.26
+0.72 (0.39%)
At close: May 23, 2025, 4:00 PM
183.25
-0.01 (-0.01%)
After-hours: May 23, 2025, 7:58 PM EDT
AbbVie Employees
AbbVie had 55,000 employees as of December 31, 2024. The number of employees increased by 5,000 or 10.00% compared to the previous year.
Employees
55,000
Change (1Y)
5,000
Growth (1Y)
10.00%
Revenue / Employee
$1,043,036
Profits / Employee
$75,545
Market Cap
323.71B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ABBV News
- 4 days ago - 69 May Aristocrats: Buy 1 Of 38 "Safer" Dividend Dogs - Seeking Alpha
- 8 days ago - 3 Stocks That Will Profit From Trump's Drug Price Cut - Benzinga
- 8 days ago - Is It Time To Buy AbbVie Stock At $180? - Forbes
- 9 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of June 3, 2025 in Cerevel Therapeutics Holdings, Inc. Lawsuit - ABBV - PRNewsWire
- 9 days ago - Dividend Checkup Amid Trump Drug Pricing Order: I Prefer AbbVie Over Pfizer - Seeking Alpha
- 10 days ago - AbbVie Inc. (ABBV) Presents at BofA Securities 2025 Healthcare Conference (Transcript) - Seeking Alpha
- 10 days ago - US FDA approves AbbVie's drug for a type of lung cancer - Reuters
- 10 days ago - U.S. FDA Approves EMRELIS™ (telisotuzumab vedotin-tllv) for Adults With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) With High c-Met Protein Overexpression - PRNewsWire